Science policy news weekly update: November 18, 2016 ?>

Science policy news weekly update: November 18, 2016

The ASBMB’s Public Affairs Department encourages all readers of the Policy Blotter to alert the office about interesting and relevant articles. Please send tips to astothert@asbmb.org.

What’s new in Blotter news?

The ASBMB’s director of public affairs, Ben Corb, provides an update on President-elect Donald Trump’s transition to the White House, including potential Cabinet members and Trump’s thoughts on immigration.

Transition update – One week in

The ASBMB released a statement underscoring its commitment to diversity and inclusion.

Statement from the ASBMB on its commitment to diversity and inclusion upon the election of Donald Trump as the president of the United States

Jonathan Sachs, an associate professor at the University of Minnesota and member of the ASBMB Public Affairs Advisory Committee, writes a guest blog post about diversity and inclusion.

Jonathan Sachs talks about inclusion

The ASBMB’s policy analyst, André Porter, discusses the NIH’s release of a notice announcing a one-time supplemental funding allowance for Kirchstein National Research Service Award recipients. This allowance will help investigators cover pay increases as a result of the Department of Labor’s new overtime rules starting Dec. 1.

NIH offers one-time relief for Kirchstein award pay gap

 

Many in the scientific community are unsure how the new Trump administration will value scientific research. Despite this lack of clarity, there’s agreement that, in order for Trump to have a successful tenure as president, he must focus on smart and creative policies that directly affect science and innovation.

Biomedical researchers ponder future after Trump election (NPR)

Science and innovation policies for Donald Trump (Nature)

 

Prior to his inauguration, Trump and his transition team are tasked with determining who will lead many of the nation’s federally funded agencies. For the scientific community, no appointment is more important than who will lead the Department of Health and Human Services. HHS encompasses many scientific agencies, including the National Institutes of Health, the Centers for Disease Control and Prevention and the Food and Drug Administration. Whoever Trump appoints as director of HHS will have great influence over the nation’s health and science policy. While many names have been floated around as contenders for this position, leaders in the biomedical research field hope for a quick decision so planning can begin.

A quick guide to the allies Trump might pick to lead HHS (STAT)

Biomedical research leaders urge Trump administration to quickly appoint an NIH director (Science)

 

One of the major pieces of legislation that the U.S. Senate will deliberate on during the lame-duck sessions is the 21st Century Cures Act. The bill aims to improve national health, including a one-time funding surge provision for the NIH. For the better part of a decade, federal funding for the NIH has been stagnant. A funding surge would help the institute fund life-saving research and ensure the U.S. stays at the forefront of medical innovation.

There’s nothing ‘lame’ about passing Cures bill (The Hill)

Leave a Reply

Your email address will not be published. Required fields are marked *